A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity ofABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands